What Is Impact BioMedical, Inc. (IBO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Impact BioMedical, Inc.'s intrinsic value is estimated at $0.13. Trading at its current price of $0.46, the valuation engine raises significant caution: 5 of 6 models flag downside risk, projecting an average implied return of -71.9%. Model dispersion is worth noting: PWERM targets $0.47 (+0.8%), versus ML-RIV at $0.01 (-98.3%). This +99.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About IBO?
6 of 13 models are currently active for IBO. Of these, 1 model suggests upside while 5 models suggest overvaluation. The Bayesian DCF estimates IBO's intrinsic value at $0.12, implying -74.8% downside from the current price. See which stocks rank higher →
How Does IBO Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, IBO ranks #270 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Impact BioMedical, Inc.'s positioning within the Pharmaceutical Preparations segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.
Is IBO a Value Trap?
CirclFi's Value Trap algorithm assigns IBO a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
6 of 13 models are active for Impact BioMedical, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Impact BioMedical, Inc. scores 4.6 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +99.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IBO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IBO's 6 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad